Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children

NCT02919046 is registered in ClinicalTrials.gov with Sinobioway Cell Therapy Co., Ltd. as lead sponsor.

NCT NCT02919046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02919046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children
Lead sponsor
Sinobioway Cell Therapy Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2016
Completion date
September 30, 2020
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory neuroblastoma